Brief: Olema Oncology Reports First Quarter 2023 Financial Results And Provides Corporate Update
09/05/2023 21:30
May 9 (Reuters) - Olema Pharmaceuticals Inc OLMA.O :
* OLEMA ONCOLOGY REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS AND
PROVIDES CORPORATE UPDATE
* OLEMA PHARMACEUTICALS INC - COMPANY EXPECTS TO PRESENT
PHASE 2
MONOTHERAPY AND INITIAL RIBOCICLIB COMBINATION CLINICAL RESULTS
IN SECOND HALF OF 2023
* OLEMA PHARMACEUTICALS INC - NET LOSS FOR QUARTER ENDED
MARCH 31,
2023, WAS $28.3 MILLION
Source text for Eikon: ID:nGNX1GTWxr
Further company coverage: OLMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Olema Pharmaceuticals
See all newsOlema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs